Anti-cytokine theraphy for Kawasaki disease

Anti-cytokine theraphy for Kawasaki disease - Anti-cytokine theraphy for Kawasaki disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012709

Enrollment

Registered

2013-12-26

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kawasaki disease

Interventions

intravenous administration of Infliximab for refractory Kawasaki disease

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: refractory Kawasaki disease(refractory to additional intravenous gamma-globulin therapy and/or sterid therapy)

Exclusion criteria

Exclusion criteria: tuberculosis infection fungus infection active type B hepatitis infection

Design outcomes

Primary

Measure	Time frame
adverse events efficacy(evaluation of coronary artery lesion)	—

Countries

Japan

Contacts

Public ContactHiroshi Katayama

Osaka Medical College Department of Pediatrics

ped100@osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026